REG - GSK PLC - Statement: Zantac (ranitidine) litigation

GSKAnnouncement

03/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240603:nRSC7445Qa&default-theme=true

RNS Number : 7445Q  GSK PLC  03 June 2024

Issued: 1 June 2024, London UK

 

Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert
Ruling

·   Scientific consensus is that there is no consistent or reliable
evidence that ranitidine increases the risk of any cancer and GSK will
continue to vigorously defend itself against all claims

·   Ruling to permit claims is not consistent with the Federal Court's
Multidistrict Litigation (MDL) ruling under the same legal standard

·   GSK disagrees with ruling by the Delaware State Court and will
immediately seek an appeal

 

 

GSK plc (LSE/NYSE: GSK) disagrees with the ruling by the Delaware State Court
and will immediately seek an appeal. The decision by the State Court
contradicts the Federal Court's MDL ruling under the same legal standard,
which dismissed all cases alleging five cancer types, in December 2022.

 

Following the 16 epidemiological studies looking at human data regarding the
use of ranitidine, the scientific consensus is that there is no consistent or
reliable evidence that ranitidine increases the risk of any cancer.

 

The litigation in Delaware remains at an early stage, and the ruling, under
the Daubert standard, relates only to the question of whether the methodology
used by plaintiffs' experts is sufficiently reliable to allow them to present
their evidence at trial.

 

The ruling does not mean that the Court agrees with plaintiffs' experts'
scientific conclusions, and it does not determine liability.

 

GSK will continue to vigorously defend itself against all claims and manage
this litigation in the best interests of shareholders. Alongside immediately
seeking an appeal to the Delaware Supreme Court, the Company will file motions
for dismissal pressing additional defenses, severance of cases, and
proof-of-use by claimants; and, at the same time, the Company will progress to
trials of individual cases.

 

GSK's capital allocation priorities remain unchanged, and the ruling has no
impact on the Company's investment plans for growth.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Simon Moore        +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Camilla Campbell   +44 (0) 7803 050238   (London)
                      Steph Mountifield  +44 (0) 7796 707505   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q1 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAEKFEDLLEAA